Inhibikase Therapeutics, Inc. (IKT): EPS (Diluted)
-$0.49
Year ended 2025-12-31
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$0.49 | n/m | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | -$1.16 | n/m | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | -$3.16 | n/c | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | -$4.28 | n/c | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | -$0.81 | n/a | 2023-03-31, From 2021-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | -$0.49 | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $0.07 | n/m |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | -$1.80 | n/m |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | -$1.59 | n/m |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | -$22.49 | n/m |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | -$0.79 | n/m |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | -$1.45 | n/m |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | -$1.76 | n/m |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | -$2.10 | n/m |
Compare IKT, VXRT, EDIT, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗